Sign Up
OverviewAPI
Shanghai Henlius Biotech and Organon achieved positive results in a phase 3 clinical trial for biosimilar HLX14, meeting primary endpoints compared to denosumab. The companies agreed on commercialization rights outside China. Henlius specializes in oncology, autoimmune, and ophthalmic treatments globally, while Organon focuses on women's health and biosimilars.

Ask a question